10x Genomics, Inc. (TXG) Stock Score, Valuation & Financial Research
10x Genomics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for TXG
10x Genomics, Inc. currently has a Wall Street Score of 26/100. The stored market price is $68.59. Its financial score is 43/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What 10x Genomics, Inc. does
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell funct
TXG financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $68.59
- Market capitalization:
- $8.71B
- Revenue:
- $638.8M
- Net income:
- $-22.7M
- Free cash flow:
- $130.1M
- Cash:
- $490.3M
- Total debt:
- $81.4M
- EPS:
- -0.35
- Financial score:
- 43/100
- Valuation score:
- 0/100
- Revenue score:
- 3/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $130.1M, showing positive cash generation.
- The balance sheet shows $490.3M of cash versus $81.4M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 43/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TXG
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.